Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?
Key PointsBioNTech needs new products to kickstart sales and earnings growth.
The personalized cancer vaccine sector is seeing a major turning point. Moderna, a frontrunner in the sector, announced impressive Phase 3 trial results for an mRNA-based cancer vaccine candidate, intismeran autogene. BioNTech, another biotech firm chasing breakthroughs in this field, has faced numerous clinical setbacks recently.
The company's stock may be a buy for risk-tolerant investors, but it's unclear whether BNTX shares are a good investment at this time. BioNTech partnered with Pfizer to develop and market Comirnaty, a leading COVID-19 vaccine, but the vaccine market demand has significantly declined, leading to a decrease in sales. BioNTech's revenue in the second quarter reached 105.6 million euros (approximately $118.3 million), a 60% decline compared to the previous year.
The company reported a net loss per share of 3.24 euros (about $3.63), compared to the 1.60 euros (about $1.79) loss per share in the prior-year quarter. Despite these setbacks, BioNTech's extensive pipeline offers hope for future success.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
